RCS - Viralgen Vector Core - Viralgen welcomes back Andy Holt as CCO

Bayer AGAnnouncement

19/10/2023 14:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231019:nRSS6948Qa&default-theme=true

RNS Number : 6948Q  Viralgen Vector Core  19 October 2023

 

 

 

 

 

Viralgen Vector Core welcomes back Andy Holt in new role as Chief Commercial
Officer

 

 

19/10/2023. San Sebastian, Spain.  Viralgen Vector Core (Viralgen) is pleased
to welcome back their previous Executive Vice President of Commercial
Development and Manufacturing, Andy Holt, into the newly created position of
Chief Commercial Officer (CCO). In this role, Holt will lead Viralgen's
commercial strategy towards achieving market-leading growth and customer
centric solutions in gene therapy manufacturing.

 

Holt brings more than 15 years of experience in cell and gene therapy into his
new role. His most recent position was CCO of Ncardia and Cellistic,
affiliated companies leveraging deep experience in induced pluripotent stem
cell (iPSC) technology to accelerate drug discovery and allogeneic cell
therapy development. Prior to his first role with Viralgen, Holt held business
development and management positions at MilliporeSigma (Merck KGaA) and Lonza.

 

"Viralgen has always worked hard to place the customer at the center of its
business," said Jimmy Vanhove, CEO of Viralgen, "and having Andy return to the
team to lead an evolving commercial organization, which includes Business
Development, Marketing, and Project Management, is an exciting next step for
us as we continue to fulfill our mission of producing revolutionary medicines
on behalf of the customers and patients we serve."

 

"It's a privilege to return to Viralgen at an exciting time in our growth",
says Holt. "We believe our team and capabilities lead the industry in meeting
the manufacturing needs of gene therapy developers for uncompromising quality,
agility, and cost effectiveness. Continuing to innovate, both in business and
science, will enable us to remain a partner of choice, and this is an
incredible opportunity that I am looking forward to supporting."

 

About Viralgen Vector Core

Viralgen is a Contract Development and Manufacturing Organization (CDMO)
founded in 2017 and exists as an independently operated subsidiary of AskBio,
which is wholly owned and independently operated as a subsidiary of Bayer AG.
As a leading manufacturer of cGMP certified AAV, Viralgen offers the Pro10™
based suspension manufacturing platform, a technology licensed from AskBio and
developed by Chief Technical Officer Josh Grieger, PhD, and co-founder R. Jude
Samulski, PhD, at University of North Carolina. It has been demonstrated
 that Pro10™ increases scalability, performance, and yield of AAV
therapies(1) at Viralgen and previous partners of AskBio. Located in Spain, in
the Gipuzkoa Science and Technology Park, Viralgen produces AAV gene therapy
treatments for pharmaceutical and biotech companies with the aim of
accelerating the delivery of new treatments that can improve patients' lives

 

The company's clinical facilities have four cGMP manufacturing suites, with
250-liter and 500-liter bioreactors. In 2020, Viralgen expanded within the
Scientific Park by constructing a new building for large-scale commercial
manufacturing. The new state-of-the-art space includes three additional cGMP
suites with a manufacturing capacity of >2,000 liters each, as well as a
suite dedicated to fully automated fill and finish operations. The new
facility has received the cGMP certification by the Spanish Agency for
Medicines and Medical Devices (AEMPS) as part of the EMA network. For more
information, visit viralgenvc.com.

 

References:

(1) Mol Ther. 2016 Feb;24(2):287-297. doi: 10.1038/mt.2015.187. Epub 2015 Oct
6.

 

For more information and interviews, please contact:

Priscilla Assumpção

comunicacion@sg-branding.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEAEENFDKDFFA